SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles planned equity and bond offerings to fund its AI infrastructure push are driving concern as shares sell off. Bears warn about dilution, debt and capital-spending risks, while bulls say the financing was expected and supports growth; many are frustrated that the stock gave back its investor-day gains.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvells announced all-stock acquisition of Lumentum has prompted concern about shareholder dilution, the deals cost, and the long wait for benefits, alongside a sharp selloff. Traders are split between viewing the move as an expensive risk and seeing strategic value in combining Marvells connectivity chips with Lumentums optical technology for AI data centers.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Marvells announced all-stock acquisition of Lumentum has put the fixed share exchange and lengthy closing timeline at the center of discussion. Many LITE traders criticize the terms and worry the value depends on Marvells share price, while others see strategic value in combining Marvells connectivity business with Lumentums optical technology for AI data centers.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsomes quarterly results, including better-than-expected revenue and loss per share alongside strong Auvelity growth, are driving discussion. Traders are split over the positive commercial momentum and narrowing losses versus continued high expenses, the lack of quantified guidance, and uncertainty about when cash-flow breakeven will arrive.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POETs apparent inclusion in Foxconns photonics ecosystem, based on a product display at its Tech Day, is fueling speculation that its optical engines are advancing toward commercialization. Bulls see it as a credibility boost, while skeptics say a demo is not a purchase order and want evidence of shipments and revenue; discussion also notes the CFO change and the upcoming earnings update.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas preliminary outlook for sharply declining DefenCath reimbursement after the first quarter of 2027 has fueled heavy selling, amid concern that lower payments could slow adoption and pressure CorMedixs revenue. Traders debate whether the warning overstates the risk, noting that DaVita said its estimates were preliminary and that CMSs initial rate and continued utilization could support demand; questions about competing ClearGuard data add to the uncertainty.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention after a breakout to a fresh 52-week high ahead of its quarterly results, with traders citing BRIUMVIs commercial momentum and anticipation around the subcutaneous program. The rally has fueled short-squeeze and buyout speculation, though some traders see it as earnings positioning and note that neither a squeeze nor a deal is confirmed.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Reported leadership changes, including an interim CEO and other executives stepping down, are prompting hopes of a management reset but also concern about added uncertainty. The debate is set against Fluences Houston manufacturing delays and repeated guidance cuts, which traders see as the core execution problem.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

FDA accelerated approval of Inovios competing RRP treatment has put pressure on Precigens PAPZIMEOS narrative, with traders debating whether the rivals dosing profile will threaten sales or whether Precigens commercial head start and established payer access will protect its position. Attention is also turning to Precigens upcoming results for evidence that PAPZIMEOS demand is continuing to build.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempuss quarterly results showed record revenue, growth in oncology testing and data businesses, and a higher full-year revenue outlook. Traders welcomed the beat and raise but debated the quality of the narrower loss, noting unrealized investment gains, while others were disappointed by the stocks sharp selloff.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
